Trajectory of FVC in Systemic sclerosis associated ILD in open label SENSCIS study Decline in FVC over 52 weeks decreased by 57% on nintedanib But am I also just seeing a study FVC decline even with nintedanib? @RheumNow #ACR23 Abs#2594 https://t.co/3h4mhm0ceU

A model for prediction of progression to RA Factors asso w/ progression -ACPAs -High % B cells -Low % NK cells Only in ACPA+ individuals Low ACPA titers, High % NK cells and Low B cells = 76% non progressors @RheumNow #ACR23 ABST2583 https://t.co/vNIwyrOJtJ

AR882 a novel and selective URAT1 inhibitor is a safe, efficacious sUA lowering, tophus resolution and with a 68% decrease in total urate crystal volume of the feet and ankles after AR882 75 mg once daily for 6 months. Keenan R, Abst#L15 #ACR23 @RheumNow https://t.co/gMCcSI1v9W https://t.co/lk3XQCaw0A

⭐️Further Assessment of a patient with rash c/w leukocytoclastic vasculitis: 👉History: ⏺️Timing, onset, progression? ⏺️Recent infectious for infectious symptoms? ⏺️Recent/new meds? ⏺️Hx of cancer? 👉Laboratory assessment for ALL: ⏺️CBC w/ diff ⏺️CMP (w/ interest in Cr,… https://t.co/tVqz6XDXt2 https://t.co/LqZpx5j0Bp

1st Large real world observational head to head study on tx of Systemic sclerosis - ILD No difference in treatment effectiveness of FVC change between tocilizumab, rituximab, mycophenolate and cyclophosphamide! @RheumNow #ACR23 Abs#2596 #ACRBest https://t.co/GaSnZSCcnZ

Fecal transplant for treatment of GI complications of systemic sclerosis? No change in those who received transplant... Overall procedure safe @RheumNow #ACR23 Abs#2597 https://t.co/TEdeGHuzpi

JAKi, especially BARI, may be useful and safe in controlling both pulmonary and joint disease in RA-ILD patients, even in refractory cases. Evolution of FVC and DLCO remained stable in first 12 months. Serrano-Combarro A, Abst#2174 #ACR23 @RheumNow https://t.co/82mMn5oh15 https://t.co/e7wrgmTOTA

Fecal microbiota - can it predict development of RA? Sadly, no. Despite promising mouse work. Despite relative control of exposure & genetic enrichment incl SE. Not even Prevotella. Maybe if you compare the most extreme cases but it’s not all the gut. #ACR23 ABST2584 @RheumNow https://t.co/VgDZaH9kvo

Pre-clinical RA trials roundup, but also: Great use (and acknowledgment) of RheumNow slide in the abstract background. Glad to see it being helpful there! #ACR23 ABST2585 @RheumNow https://t.co/sK6bDJrYjV

Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. The evolution of FVC and DLCO for 48 months remained stable with ABA therapy. Serrano-Combarro A, Abst#2173 #ACR23 @RheumNow https://t.co/QE61wzKWXi https://t.co/xd3wvMXUlA

Continued interest on CAR-T cells in systemic sclerosis! 6 mo f/up data on 3 pts who received CAR-T cell treatment - stable dz overall Skin findings improved in all 3 pts Previous finger ulcerations resolved Lung function stable in 2 pts, improved in 1 @RheumNow #ACR23 Abs#2598

#ACR23 Daily Recap - MONDAY https://t.co/PsCTB36BvR https://t.co/6cBHwm1ubY

• ACR 2023 Daily Recap - MONDAY | RheumNow

The Heart of Lupus During ACR 2023 Convergence, several abstracts were presented evaluating the prevalence of CV disease and exploring new tools to predict CV disease. The ones that caught my eye included... https://t.co/5Qk2fF3nlA #ACR23 https://t.co/Rja7K44BUf

• The Heart of Lupus | RheumNow

L16 @ #ACR23 ⭐️Can you discontinue glucocorticoids (GC) & immunosuppressive agent (IM) in stable IgG4-RD (clinically quiescent for at least 12 mo)? ➡️146 pts followed for 18 mo: 👉Group 1: withdraw GC+IM vs 👉Group 2: withdraw GC… https://t.co/j77xYm9qSN https://t.co/72IwBeEwv9